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with nZnO particles did not promote DHPN-induced lung 
carcinogenesis. However, nZnO dose-dependently caused 
epithelial hyperplasia of terminal bronchioles (EHTB) and 
fibrosis-associated interstitial pneumonitis (FAIP) that were 
independent of DHPN treatment. Tracing the fate of EHTB 
lesions in wild-type rats indicated that the hyperplastic 
lesions almost completely disappeared within 12 weeks 
after the last nZnO treatment. Since nZnO particles were 
not found in the lung and ZnCl2 solution induced similar 
lung lesions and gene expression profiles, the observed 
lesions were most likely caused by dissolved Zn2+. In sum-
mary, nZnO did not promote carcinogenesis in the lung and 
induced EHTB and FAIP lesions that regressed rapidly, 
probably due to clearance of surplus Zn2+ from the lung.
Keywords Nanosized zinc oxide particles · Lung 
toxicity · Lung carcinogenesis · Epithelial hyperplasia 
of terminal bronchioles · Interstitial pneumonitis · Lung 
fibrosis
Introduction
One of the most widely used nanomaterials is nZnO. The 
worldwide production of nZnO powder is increasing every 
year and was reported to have reached 1.4 million tons in 
2011. It is used in rubber industry and electronics and in 
commercial products such as sunscreens and paints. In 
the biomedical field, it is used in baby powders, antiseptic 
ointments, and zinc oxide tapes to treat a variety of skin 
conditions (Baldwin et al. 2001; Hughes and McLean 1988). 
Recently, nZnO has gained interest in cancer applications or 
as an active anticancer drug (Rasmussen et al. 2010).
Micron or larger-sized ZnO particles are considered 
to be “Generally Recognized as Safe” (GRAS) in food 
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additives by the FDA. However, exposure to fumes contain-
ing ZnO and other metal particles during welding or gal-
vanizing processes is known to lead to metal fume fever 
(Antonini et al. 2003; Drinker and Fairhall 1933; Fine 
et al. 1997). Recent reports have shown that nZnO affects 
cell viability and induces reactive oxygen species (ROS) 
in many mammary cell types in tissue culture (Deng et al. 
2009; Lee et al. 2008; Xia et al. 2008; Yang et al. 2009), 
cause proliferation of airway epithelial cells, goblet cell 
hyperplasia, interstitial pulmonary inflammation and fibro-
sis (Cho et al. 2011), and reversible inflammatory reac-
tion in the bronchoalveolar lavage fluid in animal studies 
(Sayes et al. 2007; Warheit et al. 2009). nZnO also leads to 
DNA damage (Kermanizadeh et al. 2012) and micronuclei 
formation in vitro (Valdiglesias et al. 2013). While these 
in vitro and in vivo studies have provided some informa-
tion on acute toxic effects of nZnO on certain cell types 
and animals, further in vivo studies are needed to deter-
mine whether nZnO has chronic toxic effects as in some 
other metal oxide particles. For example, epidemiological 
data indicate that exposures of aluminum oxide or iron 
oxide lead to pneumoconiosis in human (Hull and Abraham 
2002; Sano 1963); titanium dioxide has carcinogenic activ-
ity in the rat lung (Heinrich et al. 1995; Xu et al. 2010). 
Such chronic toxicity data will have more impact on risk 
assessment of nZnO.
Since nZnO induces inflammatory reaction, ROS pro-
duction, and genotoxicity, which are implicated in cancer 
development, in the present study, we tested the lung car-
cinogenicity of nZnO by an initiation–promotion protocol 
using human c-Ha-ras proto-oncogene transgenic (Hras 
128) rats, which have the same susceptibility to chemi-
cally induced lung carcinogenesis as their parent wild-type 
rats, but are highly susceptible to mammary tumor induc-
tion (Tsuda et al. 2005). The results indicated that nZnO 
did not have promotion effect on DHPN-induced lung and 




Forty-three female transgenic rats carrying the human 
c-Ha-RAS proto-oncogene (Hras128 rats) and 42 female 
wild-type Sprague–Dawley rats were obtained from CLEA 
Japan Co., Ltd. (Tokyo, Japan). The animals were housed 
in the Animal Center of Nagoya City University Medical 
School and maintained on a 12-h light/12-h dark cycle and 
received Oriental MF basal diet (Oriental Yeast Co. Ltd., 
Tokyo, Japan) and water ad libitum. The study was con-
ducted according to the Guidelines for the Care and Use 
of Laboratory Animals of Nagoya City University Medical 
School, and the experimental protocol was approved by the 
Institutional Animal Care and Use Committee (H22M-19).
Preparation, characterization of nZnO suspensions, and 
administration of nZnO to the lung
Zinc oxide particles (CAS No. 1314-13-2, MZ-500, with-
out coating, with a mean primary diameter of 25 nm) were 
obtained from Tayca Cooperation, Osaka, Japan. The par-
ticles were suspended in 0.1 % Tween 20 saline at 250 or 
500 μg/ml. The suspension was sonicated for 20 min to 
prevent aggregate formation.
Characterization of nZnO was conducted as follows: the 
shape of nZnO in the suspensions was imaged by transmis-
sion electron microscopy (TEM); element analysis was 
performed by an X-ray microanalyzer (EDAX, Tokyo, 
Japan), after aliquots of nZnO were loaded on a carbon 
sheet; the size distribution of nZnO in the 500 μg/ml sus-
pension was analyzed using a Particle Size Distribution 
Analyzer (Shimadzu Techno-Research, Inc., Kyoto, Japan). 
The characterization results are shown in Figure S1.
Before being administrated to rats, the nZnO suspensions 
were further sonicated for 20 min. 0.5 ml of the nZnO sus-
pensions was administrated to the lung by intra-pulmonary 
spraying (IPS) as described previously (Xu et al. 2010).
Carcinogenicity study
The carcinogenic activity of nZnO was assessed in female 
Hras128 rats using an initiation–promotion protocol by 
which we used previously to evaluate lung and mammary 
carcinogenicity of titanium dioxide nanoparticles (Xu et al. 
2010). Briefly, three groups of 10–11 female Hras128 rats 
aged 6 weeks were given 0.2 % DHPN (Wako Chemicals, 
Co., Ltd. Osaka, Japan) in the drinking water for 2 weeks, 
and Groups 4 and 5 (6 rats each) were given drinking water 
without DHPN. Two weeks later, Group 1 and Group 4 
were administered 0.1 % Tween 20 saline, and Group 2, 
Group 3, and Group 5 were administered 250, 500, and 
500 μg/ml nZnO suspensions by IPS once every two weeks 
from the end of week 4 to week 16, a total of 7 times. The 
total amounts of nZnO administered to Groups 1, 2, 3, 4, 
and 5 were 0, 0.875, 1.75, 0, and 1.75 mg/rat, respectively. 
The dosing was determined according to the permissible 
exposure limit for zinc oxide particles of the Occupational 
Safety and Health Administration (OSHA) (see Discus-
sion). Three days after the last treatment, animals were 
killed and the organs (brain, lung, liver, spleen, kidney, 
mammary gland, ovaries, uterus, and neck lymph nodes) 
were fixed in 4 % paraformaldehyde in PBS buffer adjusted 
to pH 7.3 and processed for histological examination and 
transmission electron microscopy (TEM).
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Light microscopy, polarized light microscopy, and 
transmission electron microscopy
Hematoxylin–Eosin (H&E)-stained pathological slides of 
the lung and other major organs were used to observe nZnO 
with a light microscope and polarized light microscope 
(PLM) (Olympus BX51N-31P-O polarized light micro-
scope, Tokyo, Japan) at 1,000× magnification. Localization 
of the illuminated particles was confirmed in the same 
H&E-stained sections after removing the polarizing filter.
Paraffin blocks were deparaffinized and embedded in 
epon resin and processed for nZnO observation and zinc 
element analysis, using a JEM-1010 transmission electron 
microscope (TEM) (JEOL, Co. Ltd, Tokyo, Japan) equipped 
with an X-ray microanalyzer (EDAX, Tokyo, Japan).
Immunohistochemistry and Azan–Mallory staining
PCNA was detected using an anti-PCNA monoclonal 
antibody (Clone PC10, Dako Japan Inc., Tokyo, Japan). 
The antibody was diluted 1:200 in blocking solution and 
applied to deparaffinized slides, and the slides were incu-
bated at 4 °C overnight. The slides were then incubated for 
1 h with biotinylated species-specific secondary antibodies 
diluted 1:500 (Vector Laboratories, Burlingame, CA) and 
visualized using avidin-conjugated horseradish peroxidase 
complex (ABC kit, Vector Laboratories). To assess lung 
fibrosis, paraffin-embedded slides were deparaffinized, and 
collagen fibers were visualized by Azan–Mallory staining.
Reversibility study and effects of ZnCl2 solution
To assess whether nZnO-induced terminal bronchiolar 
epithelial hyperplasia, interstitial pneumonitis, and lung 
fibrosis are reversible, we conducted reversibility experi-
ments. Seven groups of 5 female wild-type Sprague–Daw-
ley rats aged 10 weeks were administrated 0.5 ml of 0.1 % 
Tween 20 saline or 500 μg/ml nZnO suspension by IPS 
2 times per week for 4 weeks. Group 1 was treated with 
0.1 % Tween 20 saline and killed 1 day after the last IPS. 
Groups 2–7 were treated with 0.5 ml of 500 μg/ml nZnO 
suspension and killed at 1 day and 2, 4, 6, 8, and 12 weeks 
after the last IPS. For the comparison of the effects of 
zinc ion and nZnO, Group 8 was treated with 0.5 ml of 
6.17 mM ZnCl2 solution (the molecular amount is equal to 
that of 500 μg/ml nZnO suspension) by IPS at the same 
frequency and time period as the nZnO groups and killed 
1 day after the last IPS. The left lung was cut into pieces 
and frozen in liquid nitrogen for biochemical analysis, and 
the right lung was processed for histological examination. 
Other major organs were excised for histological examina-
tion, and the blood was collected for cytological and bio-
chemical analysis.
Gene expression analysis
The left lungs from Groups 1, 2, and 8 in the reversibil-
ity study described above were used for isolation of RNA. 
RNA was isolated by using TRizol reagent (Invitrogen of 
Life Technologies, CA).
For microarray analysis, 1 μg RNA from each rat of 
Group 1 was combined and 1 μg RNA from each rat of 
Group 2 was combined. The quality of the 2 mixtures of 
RNA samples was assessed and quantified using the Agi-
lent 2100 BioAnalyzer RNA Nano chip system (Agilent 
Technologies, CA) prior to further manipulation. Microar-
ray analysis was conducted by the 3-D Gene Chip (Toray 
Industries Inc., Kanagawa, Japan), and a total of 20,000 
genes were analyzed. Microarray-based pathway analy-
sis was performed by Toray Industries Inc., Kanagawa, 
Japan.
For reverse transcription-PCR (RT-PCR) and real-time 
PCR, first-strand cDNA synthesis from 1 μg of RNA was 
performed using SuperScript™ III First-Strand Synthesis 
System (Invitrogen of Life Technologies, CA) according 
to the manufacturer’s instructions. Primers are as follows: 
forward primer, 5′-TAGAATCGAGGTGCACAGGAGT-3′, 
reverse primer, 5′-TATTCCAGCAGGCTGTCAAAGA-3′, 
product size, 228 bp for Orm1; forward primer, 5′-AAGTG-
GAGGAGCAGCTGGAGTGG-3′, reverse primer, 5′-CCA 
AAGTAGACCTGCCCGGACTC-3′, product size, 155 bp 
for Tnfa, and forward primer, 5′-AGCCATGTACGTAG 
CCATCC-3′, reverse primer, 5′-CTCTCAGCTGTGGTGG 
TGAA-3′, product size, 228 bp for Actb. RT-PCR was con-
ducted using an iCycler (BioRad Life Sciences, CA) as fol-
lows: 95 °C 20 s, 60 °C 20 s, 72 °C 30 s, 30 cycles for 
Orm1; 95 °C 20 s, 60 °C 20 s, 72 °C 20 s, 25 cycles for 
Tnfa, and 95 °C 20 s, 60 °C 20 s, 72 °C 30 s, 15 cycles 
for Actb. Real-time PCR analysis of Orm1 and Tnfa 
gene expression was performed with the 7300 real-time 
PCR system (Applied Biosystem, CA) using the premix 
reagent Power SYBR Green PCR Master Mix (Applied 
Biosystem, CA) according to the manufacturer’s instruc-
tions. The Actb gene was used as the normalizing reference 
gene.
Determination of zinc ion
For detection of Zn2+ content in the lung tissue, 50–100 mg 
of the frozen lung tissues from the reversibility study 
described above were thawed at room temperature, rinsed 
with cold PBS 3 times, and homogenized for 30 s at the 
highest speed in 1 ml of T-PER, tissue protein extraction 
reagent (Pierce, Rockford, IL), with Polytron R PT 2100 
homogenizer (Capitol Scientific Inc., TX). The homoge-
nates were clarified by centrifugation at 10,000×g for 
15 min at 4 °C, and the supernatants were used for Zn2+ 
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detection. Zn2+ detection was performed using Quanti-
Chrom™ Zinc Assay kit (BioAssay Systems, CA) accord-
ing to the manufacturer’s instructions.
In vitro nZnO dissolution assay
5 μl of 500 μg/ml nZnO suspension (2.5 μg/tube) and 
increasing amounts of 1 mg/ml human α 1 acid glycopro-
tein (Sigma-Aldrich, product number G9885) or bovine 
serum albumin (Sigma-Aldrich, product number A2058) 
were added to microtubes, and the total volume of each 
tube was adjusted to 100 μl with 0.1 % Tween 20 saline. 
The final protein concentration of human α 1 acid glyco-
protein or bovine serum albumin was 0, 100, 200, 300, 400, 
and 500 μg/ml. The tubes were then incubated at 37 °C for 
2 h. The nZnO particles were removed by centrifugation at 
10,000×g for 5 min, and Zn2+ concentration in the super-
natants was determined as described above.
In vitro cytotoxicity assay
The induction and preparation of rat primary alveolar 
macrophages (PAM) has been described (Xu et al. 2010). 
5 × 103 PAMs, 1 × 103 A549 cells (human lung adenocar-
cinoma cell line), and 2 × 103 CCD34 cells (human lung 
fibroblast cell line) were seeded into 96-well culture plates 
and cultured overnight in 100 ml of RPMI 1,640 contain-
ing 10 % FBS. The cells were added with nZnO suspen-
sion or ZnCl2 solution to final concentrations of 0, 1, 5, or 
25 μg/ml of nZnO and 0, 12.3, 61.7, or 308.6 nM of ZnCl2 
(1, 5, and 25 μg/ml of nZnO are equal to 12.3, 61.7, and 
308.6 nM of ZnCl2, respectively, in the amount of zinc ele-
ment) and incubated for another 72 h. The cell viability was 
then determined using the Cell Counting Kit-8 (Dojindo 
Molecular Technologies, Rockville, MD) according to the 
manufacturer’s instruction.
Statistical analysis
Statistical analysis was performed using ANOVA. Statisti-
cal significance was analyzed using a two-tailed Student’s 
t-test. A p value of <0.05 was considered to be significant.
Results
Carcinogenesis study in Hras128 rats
DHPN-induced lung alveolar cell hyperplasia and 
adenoma development was used for the end point obser-
vation to assess the carcinogenicity of nZnO in our 
medium-term assay. As shown in Table 1, the incidence 



























































































































































































































































































































































































































































































































69Arch Toxicol (2014) 88:65–75 
1 3
alveolar cell hyperplasia and adenoma in the groups 
treated with nZnO were not significantly different from 
the DHPN alone group. In the rats which received 
nZnO treatment without prior DHPN treatment, alveo-
lar cell proliferation foci, recognized as thickening of 
the alveolar wall with proliferative alveolar epithelium, 
were observed, but significant differences from the 
saline group were not observed. In the mammary gland, 
significant inter-group difference in incidence and multi-
plicity of mammary tumors was also not observed (data 
not shown).
A notable lesion induced in all the nZnO-treated groups 
was epithelial hyperplasia of terminal bronchioles (EHTB). 
The EHTB lesions had increased cell density, often with the 
epithelial cells arranged in 1–3 layers, and partly extended 
bronchiolar structures with transition to the normal 
Fig. 1  Induction of EHTB by nZnO. a representative normal termi-
nal bronchiolar epithelium (NTBE); b EHTB in H&E-stained slides; 
c images and localizations of DHPN-induced alveolar hyperplasia 
(arrow) and nZnO-induced EHTB (arrow heads); d images of PCNA 
immunostaining in NTBE; and e in EHTB
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terminal bronchioles (Fig. 1a, b). The EHTB lesions were 
independently localized from the DHPN-induced alveo-
lar cell hyperplastic lesions (Fig. 1c). The incidences and 
multiplicity (number/cm2 lung tissue section) of EHTB in 
the groups treated with nZnO were significantly increased 
compared with that of the DHPN alone group. The increase 
was dose-dependent (Spearman rank correlation test, 
p < 0.001) (Table 1). Immunostaining with proliferating 
cell nuclear antigen (PCNA) indicated that proliferating 
bronchiolar epithelial cells were preferentially found in 
the EHTB lesions, but rarely found in the normal terminal 
bronchial epithelial areas (Fig. 1d, e).
Another lesion found in the groups treated with nZnO, 
and also independent of DHPN treatment, was intersti-
tial pneumonitis (Fig. 2a). The lesion was usually asso-
ciated with fibrosis of various thicknesses of the septal 
wall extruding into the alveolar structure (blue staining 
in Fig. 2b). Quantitative analysis indicated a significant 
increase in the fibrotic area in the rats treated with nZnO 
compared with that of rats treated with DHPN alone 
(Fig. 2c), and the increase was dose-dependent (Spearman 
rank correlation test, p < 0.001). In addition, the EHTB 
lesions often occurred near or within interstitial pneumo-
nitis areas.
Light microscopic observation of the alveoli of the 
rats treated with nZnO showed infiltration of numerous 
macrophages mixed with a few neutrophils, eosinophils, 
and lymphocytes (data not shown). The nZnO particles 
were not found in any of the alveolar macrophages; these 
macrophages contained numerous vacuolar vesicles in 
the cytoplasm (Fig. 2d). Transmission electron micro-
scopic (TEM) observation showed that nZnO particles 
were not found within the vacuolar vesicles (Fig. 2e) or 
in any alveolar tissue cells (Fig. 2f). The absence of a zinc 
peak was confirmed by elemental scanning with TEM-X-
ray microanalysis (Figure S2). nZnO particles were also 
not detected under polarized light microscope observa-
tion. This feature was in contrast with titanium dioxide 
nanoparticles which were clearly observed in alveolar 
macrophages (Figure S3).
Reversibility of EHTB and FAIP in wild-type rats
As in the Hras128 transgenic rats, nZnO induced EHTB 
and FAIP in wild-type Sprague–Dawley (SD) rats (Fig. 3a), 
and nZnO was not found in the lung tissue. nZnO-induced 
EHTB and FAIP gradually regressed with time (Fig. 3a), and 
the number of EHTB foci per square centimeter lung tissue 
section decreased from 9.81 ± 1.42 at day 1 to 0.06 ± 0.13 
at week 12 after cessation of nZnO exposure (Fig. 3b). The 
total Zn2+ content in the lung tissue also gradually decreased 
(Fig. 3c) and was positively correlated with the number of 
EHTB (r = 0.96 by Pearson correlation test).
Microarray analysis
Microarray analysis of the lung tissue indicated that nZnO 
treatment up-regulated the expression of 738 genes and 
down-regulated the expression of 267 genes (data not 
shown). The up-regulated inflammation-associated genes 
included chemotactic chemokines such as Cxcl5, Cxcl11, 
Ccl7, Cxcl2, Ccl2, and Cxcl1, proinflammatory cytokines 
such as Tnfa and Il6, and the acute-phase reactant Orm1 
(Table S1). Pathway analysis showed an increase in 
inflammatory responses in which macrophages and 
TNFα play a central role (Figure S4). The gene expres-
sion profiling was consistent with the strong inflammatory 
responses in the lung observed by histological examina-
tion. Other pathways up-regulated by nZnO included 
classical complement activation pathway, matrix metal-
loproteinase pathway, cholesterol biosynthesis pathway 
and striated muscle contraction pathway, and treatment of 
nZnO down-regulated the adipogenesis pathway (data not 
shown).
Effects of ZnCl2 solution on the lung of wild-type rats
To check whether the nZnO-induced EHTB and FAIP 
were due to dissolution of nZnO to Zn2+, we adminis-
tered ZnCl2 solution (the molecular amount is equal to 
that of 500 μg/ml nZnO suspension) to the lung of rats 
by IPS. The lesions were histologically similar to those 
observed in the nZnO-treated rats (Fig. 4a, b, c). Quan-
titative analysis of EHTB indicated that the number of 
EHTB induced by ZnCl2 solution and nZnO was compa-
rable (Fig. 4d).
To examine whether Zn2+ and nZnO have the same 
underlying molecular mechanisms, two genes, Tnfa and 
Orm1, which were determined to be up-regulated in the 
nZnO-treated rats by microarray analysis, were chosen 
for gene expression analysis. These genes were chosen 
because Tnfa-encoded tumor necrosis factor alpha is a 
multifunctional proinflammatory cytokine involved in 
a variety of acute and chronic inflammatory responses, 
and Orm1-encoded alpha 1 acid glycoprotein (AGP) is 
an acute-phase protein usually synthesized by hepato-
cytes in response to trauma, infection, and inflam-
mation (Fournier et al. 2000). RT-PCR (Fig. 4e) and 
real-time PCR (Fig. 4f) showed that treatment with 
both ZnCl2 solution and nZnO increased the expres-
sion of Tnfa and Orm1 genes in the lung tissue, with a 
little higher induction in the ZnCl2 solution treated rats. 
Similarly, increased expression of Orm1 genes was found 
in primary alveolar macrophages exposed to nZnO in 
vitro (Fig. 4g). Interestingly, addition of human AGP 
to nZnO suspension dose-dependently promoted disso-
lution of nZnO from 59.1 nmol/ml (19.7 % dissolved, 
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without addition of AGP) to 117.3 nmol/ml (39.1 % dis-
solved after addition of 500 μg/ml of AGP), while addi-
tion of bovine serum albumin (BSA) had little effect on 
dissolution of nZnO (Fig. 4h). Exposure of both nZnO 
and ZnCl2 solution resulted in dose-dependent cell death 
in vitro (Figure S5).
Fig. 2  Induction of FAIP and observation of nZnO particles. a 
representative image of FAIP in rats treated with nZnO; b image 
of Azan–Mallory staining in the lung of rats treated with nZnO, 
showing collagen fibers; c percentage of the fibrotic area in total 
lung tissue area. ***<0.001 by two-tailed Student’s t-test versus the 
vehicle group; and ###p < 0.001 by Spearman rank correlation test. 
d image showing alveolar macrophages with vacuous phagocyto-
sis vesicles; e and f TEM images showing alveolar macrophages 
(arrow) and epithelium (arrow heads), no nZnO particles being 
observed
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Effects of nZnO particles and ZnCl2 solution on other 
organs and serum of wild-type rats
Obvious lesions and macrophages containing vacuolar 
vesicles were not found in other major organs including 
the liver, kidney, spleen, or brain by histological examina-
tion (data not shown). The results of blood cell examination 
are shown in Table S2: The only changes were increased 
proportions of monocytes and eosinophils that were rap-
idly recovered within 2 weeks post exposure. Biochemical 
Fig. 3  nZnO-induced EHTB and FAIP are reversible. Wild-type rats 
were treated with 500 μg/ml nZnO by IPS 2 times/week for 4 weeks 
and killed at different time points of 1 day (1d) and 2, 4, 6, 8, and 
12 weeks (wks) after the last IPS. a histological images of the lung 
tissues; b number of EHTB per cm2 lung tissue and c Zn2+ content in 
the lung tissues at different time points. Bars = 50 μm
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Fig. 4  Similar effects of ZnCl2 solution and nZnO in induction of 
EHTB and FAIP in wild-type rats. a H&E-stained slides of the lungs 
of rats treated with vehicle; b with nZnO; and c with ZnCl2 solu-
tion, showing EHTB and FAIP; d comparable number of EHTB per 
square centimeter of the lung tissues induced by treatment of ZnCl2 
and nZnO; e gene expression determined by RT-PCR of Orm1 and 
Tnfa, with Actb gene as an internal control; f real-time PCR analy-
sis of gene expression of Orm1 and Tnfa, which was normalized with 
Actb expression; g induction of Orm1 expression in primary alveolar 
macrophages exposed to nZnO; and h effect of human alpha 1 acid 
glycoprotein (AGP) and bovine serum albumin (BSA) on dissolution 
of nZnO in vitro
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examination of serum markers for tissue and organ injuries 
indicated no significant changes compared to the vehicle 
group (Table S3). Administration of nZnO or ZnCl2 to the 
lung led to a transient increase in serum Zn2+ concentra-
tion which returned to normal levels within 2 weeks after 
administration. The elevated serum Zn2+ did not affect the 
homeostasis of the other ions examined (Table S4).
Discussion
In vivo nanomaterial toxicity usually implicates oxidative 
stress, inflammation (Nel et al. 2006), and other biologi-
cal responses depending on the individual nanomaterial. 
In vitro assays related to carcinogenicity, such as mam-
malian cell transformation and gene mutation assays, 
cannot represent the complex in vivo processes of dif-
ferent biological alterations and are not always suitable 
for risk assessment of nanomaterial carcinogenicity. In 
the present study, we tested the carcinogenic activity of 
nZnO in Hras128 rats by an initiation–promotion proto-
col, by which we previously found promotion effect of 
nanosized titanium dioxide on DHPN-induced lung and 
mammary carcinogenesis (Xu et al. 2010). nZnO did not 
show any promotion effects on lung proliferative or neo-
plastic lesions, indicating that nZnO is not carcinogenetic. 
Also, nZnO did not promote DHPN-induced mammary 
carcinogenesis.
On the other hand, nZnO was found to induce EHTB in 
Hras128 rats and wild-type SD rats. EHTB is a prolifera-
tive lesion of the terminal bronchiolar epithelium. It should 
be noted that the localization of EHTB was independ-
ent from that of DHPN-induced alveolar cell hyperplasia. 
This observation clearly indicates that the DHPN-induced 
alveolar cell hyperplasia and EHTB have different etiol-
ogy, the latter being induced by nZnO. We also observed 
2 cases of alveolar cell hyperplasia out of 6 cases in the 
nZnO alone group. This is not significant and thus con-
sidered to be spontaneous or an inflammation-associated 
event. The EHTB lesions regressed when administration of 
nZnO was discontinued and completely disappeared after 
12 weeks. Along with EHTB, the interstitial inflammatory 
changes often observed surrounding the EHTB lesions also 
regressed. Our data and other reports (Cho et al. 2011) indi-
cate that the EHTB lesions do not progress directly to can-
cers but are reactive proliferation associated with inflam-
matory events. Similar reversible inflammatory changes 
in the bronchoalveolar lavage fluids by administration of 
nanoscale or fine ZnO particles via inhalation or intratra-
cheal instillation have previously been reported (Warheit 
et al. 2009).
nZnO particles were not found in alveolar macrophages, 
in the lung tissue, or in other organs, suggesting that the 
particles were dissolved to Zn2+. Accordingly, we con-
ducted experiments to determine whether Zn2+ would 
induce similar lesions. ZnCl2 solution induced closely 
similar lung lesions and gene expression profiles as nZnO, 
demonstrating that the observed lung lesions were caused 
by Zn2+. This was confirmed by increased Zn2+ level in the 
lung and serum after administration of nZnO. Interestingly, 
treatment with nZnO up-regulated the expression of the 
Omr1 gene in both the lung and the alveolar macrophages, 
and in vitro addition of Omr1-encoded AGP dose-depend-
ently promoted nZnO dissolution. After Zn2+ was cleared 
from the lung, the EHTB and FAIP lesions disappeared, 
and this was evidenced by the positive correlation of EHTB 
number with Zn2+ content in the lung. Dissolution of nZnO 
has been reported to be particle size- and pH-dependent 
(Mudunkotuwa et al. 2012). Increased Omr1 expression 
possibly alters the microenvironment of the alveolar mac-
rophages and the lung which accelerates nZnO dissolu-
tion. The elevated Zn2+ from nZnO dissolution possibly 
interferes with zinc ion homeostasis and leads to cytotoxic 
effects (Kao et al. 2012).
According to OSHA, the permissible exposure limit for 
zinc oxide particles is 15 mg/m3 of air for total dust and 
5 mg/m3 for the respirable fraction (http://www.osha.gov
/SLTC/healthguidelines/zincoxide/recognition.html). The 
inhalation exposure limit per kilogram of body weight 
per day for the respirable fraction is 192 μg, calculated 
from 6,000 ml of minute respiratory volume and 8 work-
ing hours for a 75 kg body weight worker. The dosing in 
the carcinogenesis study of the present study was approxi-
mately 35.5 and 71 μg/kg body weight a day (calculated 
from 125 to 250 μg every two weeks for a 250 g rat) and 
is lower than the OSHA limit for humans. Since nZnO 
has more potential to be ionized than larger ZnO parti-
cles because of its higher surface area (Mudunkotuwa 
et al. 2012), this feature should be taken into regulatory 
consideration.
It has been estimated that engineered nanomaterials will 
become a $1 trillion enterprise by 2015 (Nel et al. 2006), 
and ensuring health and environmental safety is a challeng-
ing task to the nanotechnology industry. Among numerous 
engineered nanomaterials, metal based or carbon based, 
most of which have been shown to have toxic effects to at 
least some extent, nZnO is a promising nanomaterial for 
biomedical applications. The results of the present study 
indicate that, although nZnO induced reversible lung tox-
icity, it did not cause carcinogenic or chronic progres-
sive inflammatory lesions. Also, since it is biodegradable 
to ions, nZnO is easily cleared from the body (Rasmussen 
et al. 2010). Our study also suggests that the toxic effects of 
nZnO can be further decreased if efforts such as proper dos-
ing and surface coating are made to lower the Zn2+ release 
from nZnO.
75Arch Toxicol (2014) 88:65–75 
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In conclusion, treatment of nZnO by IPS did not pro-
mote lung and mammary carcinogenesis in our carcinogen-
esis model. Although nZnO induced EHTB and FAIP, the 
lesions regressed rapidly along with clearance of surplus 
Zn2+ from the lung and serum. Thus, from a toxicologi-
cal viewpoint, under the present experimental conditions, 
exposure of the lung to nZnO does not cause progressive 
neoplastic development or chronic fibrosis in the lung. 
These findings will be helpful in evaluating of the safety of 
nZnO used in biomedical applications, in which its use is 
of rather short duration, although long-term studies includ-
ing inhalation studies are required to assess their occupa-
tional and environmental health hazards.
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